Role of Dapagliflozin in Protection of Contrast Induced Nephropathy in Patients Eligible for Angiographic Procedures

Background: Dapagliflozin has proved great effects extend beyond glycemic control, including reduction in cardiovascular events, kidney disease progression, and mortality. Also, Research showed that Dapagliflozin demonstrated significant cardiorenal protective effects. This research aimed to assess the role of Dapagliflozin for reducing contrast induced nephropathy (CIN) incidence before angiographic procedures. Methods: We performed a case–control study involving 82 coronary artery disease patients undergoing PCI, 41 received dapagliflozin 10 mg daily for ≥90 days before intervention and 41 served as controls. All patients received standard hydration and non-ionic contrast. CIN was outlined as ≥25% or ≥0.5 mg/dL increase in the serum creatinine within 72 h. Results: Dapagliflozin group were associated with lower CIN incidence than those not on therapy (12.2% vs. 34.1%, p = 0.018). . Univariate analysis identified dapagliflozin use, higher baseline eGFR, and preserved ejection fraction as protective factors, while diabetes mellitus, hypertension, peripheral vascular disease, smoking, and elevated baseline creatinine were associated with higher CIN risk (p < 0.05). Multivariate logistic regression confirmed dapagliflozin use (adjusted OR 7.116, 95% CI: 1.160–43.657, p = 0.032) as well as baseline eGFR (adjusted OR 0.920, 95% CI: 0.853–0.993, p = 0.032) as independent predictors of reduced CIN risk. Conclusion: Dapagliflozin could be used for reduction of the risk of developing CIN before percutaneous coronary interventions.